AIRLINK 73.18 Increased By ▲ 0.38 (0.52%)
BOP 5.00 Decreased By ▼ -0.06 (-1.19%)
CNERGY 4.37 Increased By ▲ 0.04 (0.92%)
DFML 29.95 Decreased By ▼ -0.57 (-1.87%)
DGKC 91.39 Increased By ▲ 5.44 (6.33%)
FCCL 23.15 Increased By ▲ 0.80 (3.58%)
FFBL 33.50 Increased By ▲ 0.28 (0.84%)
FFL 9.92 Increased By ▲ 0.14 (1.43%)
GGL 10.35 Decreased By ▼ -0.05 (-0.48%)
HBL 113.01 Decreased By ▼ -0.61 (-0.54%)
HUBC 136.28 Increased By ▲ 0.08 (0.06%)
HUMNL 9.60 Decreased By ▼ -0.43 (-4.29%)
KEL 4.78 Increased By ▲ 0.12 (2.58%)
KOSM 4.72 Increased By ▲ 0.32 (7.27%)
MLCF 39.89 Increased By ▲ 1.54 (4.02%)
OGDC 133.90 Increased By ▲ 0.50 (0.37%)
PAEL 28.85 Increased By ▲ 1.45 (5.29%)
PIAA 25.00 Increased By ▲ 0.24 (0.97%)
PIBTL 6.94 Increased By ▲ 0.39 (5.95%)
PPL 122.40 Increased By ▲ 1.19 (0.98%)
PRL 27.40 Increased By ▲ 0.25 (0.92%)
PTC 14.80 Increased By ▲ 0.91 (6.55%)
SEARL 60.40 No Change ▼ 0.00 (0%)
SNGP 70.29 Increased By ▲ 1.76 (2.57%)
SSGC 10.42 Increased By ▲ 0.09 (0.87%)
TELE 8.85 Decreased By ▼ -0.20 (-2.21%)
TPLP 11.32 Increased By ▲ 0.06 (0.53%)
TRG 66.57 Increased By ▲ 0.87 (1.32%)
UNITY 25.20 Decreased By ▼ -0.05 (-0.2%)
WTL 1.55 Increased By ▲ 0.05 (3.33%)
BR100 7,674 Increased By 40.1 (0.53%)
BR30 25,457 Increased By 285.1 (1.13%)
KSE100 73,086 Increased By 427.5 (0.59%)
KSE30 23,427 Increased By 44.5 (0.19%)

A US pharmaceutical firm has identified a new subtype of the human immunodeficiency virus (HIV), and said the finding showed that cutting edge genome sequencing is helping researchers stay ahead of mutations.

The strain, HIV-1 Group M subtype L, has been recorded in three people from blood samples taken between the 1980s and 2001, all in the Democratic Republic of Congo, Abbott laboratories told AFP on Thursday.

To classify a new subtype, three cases must be discovered independently, according to guidelines issued in 2000.

Group M is the most prevalent form of the HIV-1 virus. Subtype L is now the 10th of this group and the first to be identified since the guidelines were issued.

Antiretroviral drugs, which today can reduce the viral load of an HIV carrier to the point at which the infection is both undetectable and cannot be transmitted further, have generally performed well against a variety of subtypes, according to research. But there is also some evidence of subtype differences in drug resistance.

"Since subtype L is part of the major group of HIV, Group M, I would expect current treatments to work with it," Mary Rodgers, a principal scientist and head of the Global Viral Surveillance Program at Abbott told AFP.

Copyright Agence France-Presse, 2019

Comments

Comments are closed.